Study Name: Parkinson's Disease
Clinics: Manchester EPU
Therapy Area: Parkinson's Disease
Gender and Age: Males & Females Aged 30-75
The purpose of this clinical research study is to test a study medication that is being developed as a potential treatment for Parkinson’s disease.
Currently approved treatments improve motor symptoms but do not address the underlying cause of the disease. Over time, these symptomatic therapies lose effectiveness and are associated with increasing frequency and severity of adverse effects, such as uncontrolled body movements and hallucinations. In addition, nonmotor symptoms, including depression, anxiety, sleep disorders, cognitive impairment, and dementia, are disabling and common features of Parkinson’s disease, but are poorly addressed by current therapies.
The study will last approx. 10 weeks and you will be required to attend the Manchester clinic 9 times which includes 6 – 7 overnight stays in the clinic. You will be required to swallow the active medication or placebo whole with water each day for 28 days.
Reimbursement: You will be reimbursed for your participation and reasonable travel expenses will be paid.
Key Inclusion Criteria:
Male or female aged 30 to 75
Diagnosis of Parkinson’s disease but otherwise in generally good health
BMI 18 – 35
Key Exclusion Criteria:
History of stroke or TIA (mini stroke) or heart attack within the last 12 months
History of head trauma with loss of consciousness within the last 6 months
Significant asthma, COPD or emphysema within the last 5 years
Inability to swallow whole capsules
Other eligibility criteria will apply. Please contact MAC for more information.
Any other information
Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.